HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

Published:2008-03-27 Issue:13 Volume:358 Page:1409-1411
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Paik Soonmyung,Kim Chungyeul,Wolmark Norman

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMc0801440

Cited by 393 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expanding the treatment options for HER2-low metastatic breast cancer: Experience with trastuzumab deruxtecan in aggressive luminal HER2-low breast cancer;Meditsinskiy sovet = Medical Council;2024-07-24

2. Trastuzumab Accessibility and Utilization for Breast Cancer Treatment in an eastern prefecture-level city in China: Does health insurance coverage matter?;2024-07-18

3. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models;British Journal of Cancer;2024-04-10

4. ATM-mediated co-chaperone DNAJB11 phosphorylation facilitates α-synuclein folding upon DNA double-stranded breaks;NAR Molecular Medicine;2024-04-01

5. Potential Role of Nrf2, HER2, and ALDH in Cancer Stem Cells: A Narrative Review;The Journal of Membrane Biology;2024-02-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP